Partnering with Aastrom
Aastrom is the leader in the development of patient-specific, multi-cellular therapies for the treatment of severe, chronic cardiovascular diseases. We are interested in collaborating with other pharmaceutical companies that can help us maximize the clinical and commercial potential of our products. Our most advanced product candidate, ixmyelocel-T, has entered pivotal Phase 3 clinical development as a potential treatment for patients with the most severe form of peripheral arterial disease (PAD), critical limb ischemia (CLI), who have no other treatment options.
Contact us for more information about partnering with Aastrom.